Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
ConditionMyelofibrosis
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorCellenkos, Inc.
About this trial
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
Eligibility criteria
Qualifiers
Ability to comprehend and willingness to sign a written informed consent form (ICF) for the study.
Age above 18 years inclusive at the time of signing the ICF.
Participants who fulfill the diagnostic criteria of myelofibrosis including primary myelofibrosis and myelofibrosis arising from polycythemia vera and essential thrombocythemia
Life expectancy is greater than 6 months.
Disqualifiers
Any major surgery within 28 days before the first dose of study treatment.
Undergone any prior allogenic or autologous stem cell transplantation or a candidate for such transplantation.
Received chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating agent to treat the participant's disease, with the exception of ruxolitinib, within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.
Participant has received splenic irradiation within the past 6 months.
Trial design
Treatments tested in this trial
- CK0804
Treatment groups
24 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov